Fluoride for treating postmenopausal osteoporosis
- 23 October 2000
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (7) , CD002825
- https://doi.org/10.1002/14651858.cd002825
Abstract
To assess the efficacy of fluoride therapy on bone loss, vertebral and non-vertebral fractures and side effects in postmenopausal women. We searched Medline, Current Contents and the Cochrane Controlled Trial Registry up to December 1998. Two independent reviewers selected RCTs which met predetermined inclusion criteria. Two reviewers independently extracted data using predetermined forms and assessed the methodological quality of the trials using a validated scale. For dichotomous outcomes, relative risks (RR) were calculated and for continuous outcomes, weighted mean differences (WMD) of percentage change from baseline were calculated. Where heterogeneity existed (determined by a chi-square test) a random effects model was used. Eleven studies (1429 subjects) met the inclusion criteria. The increase in lumbar spine bone mineral density (BMD) was found to be higher in the treatment group than in the control group with a WMD 8.1% (95%CI: 7.15,9.09) after two years of treatment and 16.1%(95%CI: 14.65,17.5) after four years. The RR for new vertebral fractures was not significant at two years [0.87 (95%CI: 0.51,1.46)] or at four years [0.9(95%CI: 0.71,1.14)]. The RR for new non-vertebral fractures was not significant at two years 1.2(95%CI: 0.68,2.1) but was increased at four years in the treated group 1.85(95%CI: 1.36,2.5), especially if used at high doses and in a non slow release form. The RR for gastrointestinal side effects was not significant at two years 2.18(95%CI: 0.86,1.21) but was increased at four years in the treated group 2.18(95%CI: 1.69,4.57) especially if fluoride was used at high doses and in a non slow release form. The number of withdrawals and dropouts was not different between treated and control groups at two and four years. Although fluoride has an ability to increase BMD at lumbar spine, it does not result in a reduction of vertebral fractures. In increasing the dose of fluoride, one increases the risk of non-vertebral fracture and gastrointestinal side effects without any effect on the vertebral fracture rate.Keywords
This publication has 55 references indexed in Scilit:
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Comparison of serum fluoride levels after administration of monofluorophosphate-calcium carbonate or sodium fluoride: differences in peak serum concentrationsJournal of Molecular Medicine, 1994
- Hinweis auf fluoridinduzierte Effekte am Kalkaneus durch Messungen der Breitband-Ultraschallabschwächung (BUA)RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 1994
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993
- Fluoride therapy in postmenopausal osteopenic women: Effect on vertebral and femoral bone density and prediction of bone responseOsteoporosis International, 1991
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990
- Long-term fluoride therapy of postmenopausal osteoporosisBone, 1986
- Effect of sodium fluoride, calcium, phosphate, and vitamin D2 on trabecular bone balance and remodeling in osteoporoticsBone, 1985
- Extended treatment of primary osteoporosis by sodium fluoride combined with 25 hydroxycholecalciferolClinical Rheumatology, 1984
- Effect of the Fluoride/Calcium Regimen on Vertebral Fracture Occurrence in Postmenopausal OsteoporosisNew England Journal of Medicine, 1982